Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Iovance Biotherapeutics (IOVA) over the last 11 years, with Dec 2024 value amounting to $115.7 million.

  • Iovance Biotherapeutics' Cash & Equivalents fell 3.69% to $158.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.1 million, marking a year-over-year decrease of 3.69%. This contributed to the annual value of $115.7 million for FY2024, which is 0.70% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Cash & Equivalents stood at $115.7 million, which was up 0.70% from $114.9 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Cash & Equivalents registered a high of $115.7 million during FY2024, and its lowest value of $114.9 million during FY2023.
  • Over the past 2 years, Iovance Biotherapeutics' median Cash & Equivalents value was $115.3 million (recorded in 2023), while the average stood at $115.3 million.
  • Data for Iovance Biotherapeutics' Cash & Equivalents shows a peak YoY climbed of 0.70% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Cash & Equivalents (Yearly) stood at $114.9 million in 2023, then increased by 0.70% to $115.7 million in 2024.